Acta Scientific Clinical Case Reports

Case Report Volume 1 Issue 8

Pancreatic Insulinoma - The Once in a Blue Moon Oncological Episode

Ismail Abdillahi Iltireh1, Robleh Hassan Farah2, Carlo Astini3, Median Said4, Christiane Osman Glele5 and Divya Dhananjay Singh1*

1Associate Surgeon, Department of General Surgery, Hospital Military Djibouti, Soudan
2Associate Surgeon of the Hospital Cheikho the Balballa, Djibouti, Soudan
3Visiting Surgeon, Department of General Surgery, Hospital Military Djibouti, Soudan
4Senior Consultant Anaesthesia, Department of Anaesthesia, Hospital Military Djibouti, Soudan
5Resident Anaesthetist, Department of Anaesthesia, Hospital Military Djibouti, Soudan

*Corresponding Author: Divya Dhananjay Singh, Associate Surgeon, Department of General Surgery, Hospital Military Djibouti.

Received: July 08, 2020; Published: August 12, 2020



 Insulinoma is primarily a pancreatic neuroendocrine tumour, known to be rare and benign, in 90% of cases, while 10% cases are developed in Multiple Endocrine Neoplasia patients. The age of onset is 50 years, except for the malignant forms related to the MEN syndrome cases, where it appears between 20 and 40 years of age. The clinical findings and blood chemistry parameters coupled with the imaging techniques (Echo-endoscopy, CT, MRI) make it possible to locate the tumour in 80% of cases. The treatment of choice is essentially surgical, such as enucleation or removal of part of the pancreas.

Keywords: Pancreas; Hypoglycemia; Endocrine Tumour; Neuroendocrine Tumour



  1. Service FJ., et al. “Functioning insulinoma: incidence, recurrence, and long term survival of patients: a 60-year study”. Mayo Clinic Proceedings 7 (1991): 711-719.
  2. Liu Y., et al. “The value of multidetector-row CT in the preoperative detection of pancreatic insulinomas”. Radiology Medicine8 (2009): 1232-1238.
  3. Fidler JL., et al. “Preoperative detection of pancreatic insulinomas on multiphasic helical CT”. American Journal of Roentgenology 3 (2003): 775-780.
  4. Rich TA and Perrier ND. “Multiple endocrine neoplasia syndromes”. Surgical Clinics of North America 4 (2008): 863-895.
  5. Bégu-Le Corroller A., et al. “Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients”. Diabetes Metabolism4 (2008): 343-348.
  6. Horton K., et al. “Multi-detector row CT of pancreatic islet cell tumors”. Radio Graphics 2 (2006): 453-464.
  7. Graves TD., et al. “Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder”. Journal of Neurology, Neurosurgery, and Psychiatry 8 (2004): 1091-1092.
  8. Elisabeth AM., et al. “Giant insulinoma: case report and review of the literature”. The Journal of Clinical Endocrinology and Metabolism 1 (2004): 575-580.
  9. Sebbag-Sfeza D., et al. “Insulinome pédiculé au bord antérieur de la tête du pancréas: une localisation exceptionnelle à connaître”. Journal de Radiologie Diagnostique et Interventionnelle 3 (2013): 335-338.
  10. Proye C and Lokey JS. “Current concepts in functioning endocrine tumors of the pancreas”. World Journal of Surgery 12 (2004): 1231-1238.
  11. Peix J-L and Proye C. “Stratégie et technique dans le traitement chirurgical des tumeurs endocrines duodénopancréatiques”. Techniques chirurgicales Appareil digestif1 (2006): 883-891.
  12. De Herder WW., et al. “Well differentiated pancreatic tumor/carcinoma: insulinoma”. Neuroendocrinology3 (2006): 183-188.
  13. Kulke MH., et al. “Glycemic control in patients with insulinoma treated with everolimus”. The New England Journal of Medicine 2 (2009): 195-197.
  14. Jensen RT., et al. “ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes”. Neuroendocrinology 2 (2012): 98-119.
  15. Ong GS., et al. “Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma”. European Journal of Endocrinology 5 (2010): 1001-1008.
  16. Falconi M., et al. “ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors”. Neuroendocrinology2 (2012): 120-134.
  17. Hill JS., et al. “Pancreatic neuroendocrine tumors: the impact of surgical resection on survival”. Cancer 4 (2009): 741-745.
  18. Ketari-Jamoussi S., et al. “Un insulinome géant: à propos d'un cas”. Annales d'Endocrinologie1 (2009): 71-75.
  19. Baudin E., et al. “Recommendations pour la prise en charge de l'insulinome malin”. La Presse Médicale 6 (2014): 645-659.


Citation: Ismail Abdillahi Iltireh., et al. “Pancreatic Insulinoma - The Once in a Blue Moon Oncological Episode". Acta Scientific Clinical Case Reports 1.8 (2020): 03-07.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.278

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US